Drug Search Results
More Filters [+]

Ronacaleret

Alternative Names: ronacaleret, sb-751689, sb 751689, sb751689
Latest Update: 2018-08-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CaSR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ronacaleret

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Other|Osteoporosis

Phase 1: Osteoporosis|Stem Cell Transplant|Bone Marrow Transplantation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Ronacaleret

P1

Completed

Stem Cell Transplant

2013-04-02

NCT01466335

P1

Completed

Bone Marrow Transplantation|Stem Cell Transplant

2012-03-05

2007-001477-29

P2

Terminated

Unknown

2009-01-10

Study CR9108963

P2

Terminated

Osteoporosis

2008-12-26

Recent News Events

Date

Type

Title